The bulletin of the Yamaguchi Medical School

PISSN : 0513-1812
EISSN : 2436-696X

Back to Top

The bulletin of the Yamaguchi Medical School Volume 52 Issue 3-4
published_at 2005-12

Development of new therapy in fulminant hepatitis from glucagon-insulin therapy to bone marrow cell transplantation

Development of new therapy in fulminant hepatitis from glucagon-insulin therapy to bone marrow cell transplantation
Okita Kiwamu
Terai Shuji
Omori Kaoru
Aoyama Kouji
fulltext
649 KB
A020052000301
Application of cell therapy using stem cell into intractable diseases has been noted as the medicine in the next generation taking the place of organ transplantation. Bone marrow cells have been focused as a candidate of the source of this therapy. Liver failure is a terminal state of all advanced liver diseases and thousands of patients are dying of decompensated liver cirrhosis in every year in Japan. Liver transplantation must be the strongest weapon to relieve those patients. However, particularly in Japan, liver transplantation has not been popularized. In this sense, we thought of autologous bone marrow cells transplantation for decompensated liver cirrhosis. Basic studies using animal model revealed that transplanted bone marrow cells into syngenic mouse suffering from liver cirrhosis migrated into the damaged liver and transdifferentiated to the hepatocytes. Based upon the animal studies, clinical trial of this new cell therapy supported by the Ministry of Health, Labor and Welfare is ongoing. It is early to estimate this therapy. However, free from liver failure has been observed in some cases.
Creator Keywords
fulminant hepatitis
fulminant hepatic failure
glucagon-insulin therapy bone marrow cell transplantation
stem cell